Salvage computed tomography-guided brachytherapy for patients with postoperative vaginal recurrence of endometrial cancer

When a woman is diagnosed with endometrial cancer, the most common first step is surgery to remove the uterus. Doctors then look at the tissue under a microscope to decide if the cancer is likely to come back. If the risk is high, they often add radiation or chemotherapy to lower that risk. However, even with these precautions, the cancer can sometimes return, specifically in the tissue of the vagina where the surgery took place. When this happens, the goal shifts to saving the patient's life and stopping the cancer from spreading further. The challenge for doctors is figuring out the best way to deliver radiation to a small, specific area that has already been operated on, without damaging the nearby bladder or intestines. This delicate balance requires precise targeting, and the tools used to see and treat the cancer have evolved significantly in recent years.

A team of researchers at Tohoku University in Japan recently looked back at how they treated fifty women who faced this exact situation. These women had surgery for endometrial cancer, and later, the cancer returned in their vaginas. None of these women had received radiation therapy before, which meant they were candidates for a second round of treatment. The doctors used a technique called brachytherapy, which involves placing a radiation source directly inside or very close to the tumor. To make sure the radiation hit the right spot, they used a CT scanner, the same type of machine used for detailed X-rays, to guide the placement of tiny needles or applicators. This method allowed them to see the tumor and the surrounding organs in real-time, ensuring the radiation dose was high enough to kill the cancer cells but low enough to protect healthy tissue.

The study focused on two main groups of patients. In one group, the doctors could see the returning tumor clearly on the CT scans; in the other group, the tumor was too small to be seen on the images. Vaginal recurrence was identified by visual examination and confirmed by cytology or histological evaluation, but the distinction between the groups relied on whether the tumor was detectable on imaging. The treatment plan varied based on what the doctors saw. For those with visible tumors, the radiation was delivered in fewer sessions, but with a higher total dose. For those with invisible tumors, the treatment was spread out over more sessions, though the total dose was generally lower. The researchers calculated the total radiation dose the tumor received, converting different types of radiation schedules into a single standard number to compare them fairly. They found that the average dose delivered to the high-risk area was 70.5 Gy.

The results showed that this approach was highly effective at stopping the cancer in the vagina. After three years, about 86% of the women had no sign of the cancer returning in that specific area. The researchers discovered a clear link between the amount of radiation the tumor received and the success of the treatment. When the tumor received a dose of at least 67.3 Gy, the local control rate was perfect, with no recurrences in that group. However, when the dose was lower, the cancer came back more often. This was particularly noticeable in the group with invisible tumors, who received lower doses and experienced more local failures. The study suggests that even when a tumor is too small to see, it still needs a strong dose of radiation to be controlled effectively.

Despite the success in controlling the cancer locally, the study highlighted a significant remaining challenge. While the radiation stopped the cancer in the vagina, many patients still developed new cancer spots in other parts of their bodies, such as the lungs or lymph nodes. By the three-year mark, nearly half of the patients had experienced a recurrence somewhere in their body, and distant metastasis was the primary reason for treatment failure. The researchers found that patients with visible tumors and those who had higher-risk features from their original surgery were more likely to develop these distant problems. This indicates that while the local treatment is working well, the cancer may have already spread microscopically to other areas before the vaginal recurrence was even detected.

The study also looked at the safety of the treatment. Most patients did not suffer from severe side effects, but a small number experienced complications. Three patients developed severe vaginal inflammation, which the researchers noted occurred after they started taking a specific medication called lenvatinib for their cancer. This drug is known to help fight cancer but can also slow down the healing of tissues that have been treated with radiation. Two other patients had moderate inflammation in their rectum. These findings serve as a reminder that combining radiation with certain cancer drugs requires careful timing and monitoring to avoid damaging healthy tissue.

Ultimately, this research confirms that using CT scans to guide radiation therapy is a powerful tool for treating vaginal recurrence of endometrial cancer. It offers a high chance of curing the cancer in the vagina, provided the doctors deliver a sufficient dose. However, the study also makes it clear that controlling the cancer in one spot is not enough if it has already spread elsewhere. The authors suggest that for patients with visible tumors or high-risk factors, doctors should consider adding whole pelvic radiation or other systemic treatments to address the risk of distant spread. For now, the best strategy appears to be a combination of precise, high-dose local treatment and vigilant monitoring to catch any new problems early, ensuring that the focus remains on both the local battle and the broader war against the disease.